FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma
Autor: | Elie W. Akl, Elio Adib, Talal El‐Zarif, Toni K. Choueiri, Charlene Mantia, Rohit Jain, William Paul Skelton, Praful Ravi, Dory Freeman, David J. Kwiatkowski, Catherine Curran, Amin Nassar, Guru Sonpavde |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2022 |
Předmět: |
enfortumab vedotin
Metastatic Urothelial Carcinoma Bladder cancer business.industry medicine.medical_treatment Enfortumab vedotin biomarkers General Medicine medicine.disease targeted therapy Article Diseases of the genitourinary system. Urology Targeted therapy Cancer research genomics Medicine bladder cancer RC870-923 business |
Zdroj: | BJUI Compass, Vol 3, Iss 2, Pp 169-172 (2022) BJUI Compass |
ISSN: | 2688-4526 |
Popis: | Enfortumab Vedotin (EV) is approved for metastatic urothelial carcinoma (mUC) progressing post-platinum and PD1/L1 inhibitor therapy. Erdafitinib is approved for post-platinum mUC with activating somatic genomic alterations (GAs) in FGFR2/3. Information on the activity of EV in mUC with FGFR2/3 alterations will facilitate optimal clinical management. In this multi-center, retrospective analysis, we assessed the overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) to EV in mUC patients with and without FGFR2/3 GAs including mutations and fusions. Multivariable cox-regression and logistic regression analyses with 2-tailed p-values were used to evaluate the association of GAs with outcomes. A majority of the evaluable 60 patients were male (44/60, 78%), exhibited ECOG performance score 0–1 (53/60, 88.3%) and had a median age of 70.5 (range 48 – 88) years when starting EV. GAs in FGFR2/3 did not influence the ORR (p=0.32), OS (p=0.79) or PFS (p = 0.32) with EV. In conclusion, FGFR2/3 GAs did not appear to compromise major outcomes with EV in mUC. Larger studies are required to further evaluate the impact of FGFR2/3 GAs on the activity of EV and the optimal sequencing of EV and erdafitinib in mUC. |
Databáze: | OpenAIRE |
Externí odkaz: |